Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
CA | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 15, 23 | -0.43 Increased by +68.15% | -0.42 Decreased by -2.38% |
| Aug 14, 23 | 0.43 Increased by +139.81% | 0.41 Increased by +4.88% |
| May 9, 23 | -0.50 Increased by +37.50% | -0.65 Increased by +23.08% |
| Mar 16, 23 | -0.83 Decreased by -9.21% | -0.83 |
| Nov 14, 22 | -1.35 Decreased by -90.14% | -1.13 Decreased by -19.47% |
| Aug 11, 22 | -1.08 Increased by +29.41% | -0.83 Decreased by -30.12% |
| May 12, 22 | -0.80 Increased by +38.46% | -0.81 Increased by +1.23% |
| Mar 10, 22 | -0.76 Increased by +31.53% | -0.69 Decreased by -10.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.24 M Increased by +24.22% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.56 M Decreased by -20.77% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -10.99 M Decreased by -52.91% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -13.56 M Decreased by -102.72% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -10.87 M Increased by +3.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -7.92 M Increased by +0.89% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -7.19 M Decreased by -52.85% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -6.69 M Decreased by -77.78% | Decreased by N/A% Decreased by N/A% |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.